Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study



Document title: Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study
Journal: The brazilian journal of infectious diseases
Database: PERIÓDICA
System number: 000290692
ISSN: 1413-8670
Authors: 1
2
Institutions: 1Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil
2Universidade Federal de Goias, Hospital das Clinicas, Goiania, Goias. Brasil
Year:
Season: Ago
Volumen: 6
Number: 4
Pages: 157-163
Country: Brasil
Language: Inglés
Document type: Artículo
Approach: Caso clínico, analítico
English abstract ABSTRACT OBJECTIVES: Evaluation of the effectiveness, safety and tolerability of gatifloxacin in the treatment of outpatients with community-acquired pneumonia (CAP). STUDY DESIGN: A prospective, multicenter, non-comparative clinical study carried out in Brazil. Voluntary, unpaid physician participation contributed to an unbiased study design. PATIENTS: Adult outpatients with clinical diagnosis of CAP. REGIMEN: Gatifloxacin, 400 mg PO once daily for 7 to 14 days. STUDY PROCEDURES: Initial clinical assessment, at the first day of gatifloxacin therapy; final evaluation after 7 to 14 days of treatment. RESULTS: According to the physicians' assessments 97.3% of patients were cured or improved after gatifloxacin treatment. The incidence of adverse events was low and the most commonly reported events were nausea and dyspepsia. CONCLUSIONS: Gatifloxacin, 400 mg PO once daily for 7 to 14 days, is effective and safe in the treatment of patients with CAP
Disciplines: Medicina
Keyword: Farmacología,
Microbiología,
Terapéutica y rehabilitación,
Gatifloxacina,
Pneumonia
Keyword: Medicine,
Microbiology,
Pharmacology,
Therapeutics and rehabilitation,
Gatifloxacin,
Pneumonia
Full text: Texto completo (Ver HTML)